Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience

Urologia Internationalis, 03/29/2012

The relatively high rates of biochemical response support the use of cryotherapy as a salvage procedure for radiorecurrent prostate cancer.


  • Between February 2006 and August 2008, 19 patients underwent salvage cryotherapy for radiorecurrent prostate cancer.
  • Post-radiotherapy recurrence was confirmed by prostatic biopsy.
  • The ‘Phoenix definition’ was used to define biochemical failure after salvage cryotherapy.


  • The mean age at cryotherapy was 69.2 years and the mean time from radiotherapy to cryotherapy was 72.3 months.
  • Patient characteristics prior to cryotherapy included a mean PSA level of 6.84 ng/ml and a median Gleason score of 7.
  • The mean post-cryotherapy follow-up was 33.3 months.
  • The 2-year biochemical disease-free survival rate was 58%.
  • The median post-cryotherapy PSA nadir was 0.20 ng/ml (range 0.005–8.260).
  • There were no procedure-related or cancer-related deaths.

Print Article Summary Cat 2 CME Report